Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells.
Open Access
- 4 January 1996
- journal article
- Published by Elsevier in Journal of Lipid Research
- Vol. 37 (1) , 148-158
- https://doi.org/10.1016/s0022-2275(20)37643-4
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteinsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Enzymatic cyclization of squalene and oxidosqualene to sterols and triterpenesChemical Reviews, 1993
- Preferential cyclization of 2,3(S):22(S),23-dioxidosqualene by mammalian 2,3-oxidosqualene-lanosterol cyclaseBiochemical and Biophysical Research Communications, 1992
- Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism.Journal of Clinical Investigation, 1990
- Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of CholesterolNew England Journal of Medicine, 1990
- Lovastatin and Simvastatin - Inhibitors of HMG CoA Reductase and Cholesterol BiosynthesisCardiology, 1990
- Bioorganic characterization and mechanism of the 2,3-oxidosqualene .fwdarw. lanosterol conversionJournal of the American Chemical Society, 1982
- Mechanism of cataract production by 3-β(2-diethylaminoethoxy) androst-5-en-17-one hydrochloride, U18666A: An inhibitor of cholesterol biosynthesisExperimental Eye Research, 1979
- Biological Activity of Some Oxygenated SterolsScience, 1978
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959